老年医学与保健2013，Vol.19Issue(1)：17-20,4.DOI:10.3969/j.issn.1008-8296.2013-01-06
老年弥漫性大B细胞淋巴瘤预后因素及治疗分析
Analysis of the prognosis-related factors and therapy for elderly patients with diffuse large B-cell lymphoma
摘要
Abstract
Objective To discuss the prognosis-related factors for elderly patients with diffuse large B-cell lymphoma and survival analysis of different therapy. Methods We retrospectively analyzed the clinical data from 72 elderly patients with initial diffuse large B-cell lymphoma. The evaluable 64 cases were eligible. The parameters included gender, age, clinical stage, B symptom, ECOG performance status (ECOG-PS), extra lymphnodes invasion, serum level of lactate dehydrogenase (LDH), hemoglobin level, international prognostic index (IPI). The survival analysis and Cox proportional hazards regression model were conducted. To We also compared the survival of 34 patients who received 3-week CHOP chemotherapy and 30 patients 3-week R-CHOP chemotherapy. Results The median follow-up of the total study population was 40.3 months. The estimated 2-year overall survival (OS) of all patients was 67.43%, the estimated 3-year OS was 49.89%. In the multivariate analysis that include age, clinical stage, ECOG-PS, IPI were the independent factor predicting overall survival (P< 0.05). The estimated 2-year OS (53.3% vs 72.1%, P< 0.05) and 3-year OS (39.2%vs60.8%, P< 0.05) had significant difference between CHOP and R-CHOP group. Conclusion Age, clinical stage, ECOG-PS, IPI were independent predictive and prognostic factor in elderly patients with DLBCL. R-CHOP chemotherapy has more advantages than CHOP chemotherapy in survival.关键词
弥漫性大B细胞淋巴瘤/老年人/预后/生存分析Key words
Diffuse large B-cell lymphoma/ Elderly patients/ Prognosis/ Survival analysis分类
医药卫生引用本文复制引用
沈琳,王振荣,张洪娣,沙颖豪,谢彦晖..老年弥漫性大B细胞淋巴瘤预后因素及治疗分析[J].老年医学与保健,2013,19(1):17-20,4.基金项目
上海市卫生局重点科研基金(20114025) （20114025）
